Recarbrio

imipenem/cilastatin/relebactam · Merck & Co.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Recarbrio, covering 2019-07-16 to 2026-01-26. Get the full timeline:

Most recent: EMA Authorised: Recarbrio (imipenem monohydrate;cilastatin sodium;relebactam monohydrate) — Merck Sharp & Dohme B.V.